JP2024508746A5 - - Google Patents
Info
- Publication number
- JP2024508746A5 JP2024508746A5 JP2023549549A JP2023549549A JP2024508746A5 JP 2024508746 A5 JP2024508746 A5 JP 2024508746A5 JP 2023549549 A JP2023549549 A JP 2023549549A JP 2023549549 A JP2023549549 A JP 2023549549A JP 2024508746 A5 JP2024508746 A5 JP 2024508746A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antigen
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150475P | 2021-02-17 | 2021-02-17 | |
| US63/150,475 | 2021-02-17 | ||
| PCT/US2022/016776 WO2022178114A1 (en) | 2021-02-17 | 2022-02-17 | Compositions comprising 4-1bb and ox40 binding proteins and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508746A JP2024508746A (ja) | 2024-02-28 |
| JP2024508746A5 true JP2024508746A5 (cg-RX-API-DMAC10.html) | 2025-02-21 |
Family
ID=80738990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549549A Pending JP2024508746A (ja) | 2021-02-17 | 2022-02-17 | 4-1bbおよびox40結合タンパク質を含む組成物および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240150483A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4294843A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024508746A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230167025A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117203236A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022223692A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3208339A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022178114A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120584137A (zh) | 2023-01-06 | 2025-09-02 | 阿帕特夫研究和发展有限公司 | 双特异性pd-l1和cd40结合分子以及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| BR112017024770A2 (pt) * | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
| NZ757965A (en) * | 2017-03-16 | 2022-07-01 | Lg Chemical Ltd | Liquid formulation of anti-tnf alpha antibody |
| AU2019301206B2 (en) * | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| JP7539897B2 (ja) * | 2019-01-16 | 2024-08-26 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | ヒトcd137に結合する抗体の製剤およびその使用 |
| MX2022001882A (es) * | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
-
2022
- 2022-02-17 KR KR1020237031740A patent/KR20230167025A/ko active Pending
- 2022-02-17 CN CN202280028792.6A patent/CN117203236A/zh active Pending
- 2022-02-17 US US18/546,751 patent/US20240150483A1/en active Pending
- 2022-02-17 CA CA3208339A patent/CA3208339A1/en active Pending
- 2022-02-17 WO PCT/US2022/016776 patent/WO2022178114A1/en not_active Ceased
- 2022-02-17 AU AU2022223692A patent/AU2022223692A1/en active Pending
- 2022-02-17 JP JP2023549549A patent/JP2024508746A/ja active Pending
- 2022-02-17 EP EP22710217.5A patent/EP4294843A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021245178B2 (en) | Stabilized antibody-containing liquid formulations | |
| TWI860988B (zh) | 低ph藥物製劑 | |
| JP6469765B2 (ja) | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 | |
| CN106075434B (zh) | 含高浓度抗体的溶液制剂 | |
| EP3195880B1 (en) | High concentration anti-sclerostin antibody formulations | |
| JP2020518600A5 (cg-RX-API-DMAC10.html) | ||
| EP3681483B1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| JP2024508762A5 (cg-RX-API-DMAC10.html) | ||
| RU2012131099A (ru) | Препарат антитела | |
| JP2020509031A5 (cg-RX-API-DMAC10.html) | ||
| CN112741804A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2024540377A5 (cg-RX-API-DMAC10.html) | ||
| JP2026016480A5 (cg-RX-API-DMAC10.html) | ||
| JP2023528068A (ja) | レビリマブの水性医薬組成物 | |
| RU2025101286A (ru) | ФАРАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ РЕЦЕПТОРА ПРОГРАМИРУЕМОЙ СМЕРТИ 1 (PD-1) И rHuPH20 ИЛИ ИХ ВАРИАНТОВ ИЛИ ФРАГМЕНТОВ | |
| JP2024543931A5 (cg-RX-API-DMAC10.html) | ||
| JP2023501155A (ja) | クリザンリズマブ含有抗体製剤 | |
| HK40047490A (en) | Stable preparation containing anti-pd-l1 antibody | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein |